ankyrin repeat domain 20 family member A21, pseudogeneGenealiases: []
Q-omics provides the consensus-scored ANKRD20A21P profile across patient tissues and cancer cell-line models. ANKRD20A21P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ANKRD20A21P is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, ANKRD20A21P RNA expression shows 15,949 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, KICH, and UVM as cancer lineages where ANKRD20A21P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD20A21P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD20A21P survival associations across molecular data types. ANKRD20A21P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD20A21P RNA expression–survival associations across cancer types. High ANKRD20A21P expression shows unfavorable associations in KICH, UVM and UCEC, but favorable associations in UCS, MESO and ACC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UCS as the clearest survival context for ANKRD20A21P RNA expression.
This table summarizes ANKRD20A21P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD20A21P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD20A21P shows lower tumor expression in KICH, BRCA, LUAD, THCA and COAD and higher tumor expression in PRAD. The KICH box plot shows higher ANKRD20A21P RNA expression in normal versus tumor tissue (log2 FC = −0.123, t-test p < 0.001).
This table shows molecular features associated with ANKRD20A21P in patient tissues and cancer cell lines. In patient samples, ANKRD20A21P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD20A21P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT.
